Time-dependent and somatically acquired mitochondrial DNA mutagenesis and respiratory chain dysfunction in a scleroderma model of lung fibrosis
- PMID: 24939573
- PMCID: PMC4061543
- DOI: 10.1038/srep05336
Time-dependent and somatically acquired mitochondrial DNA mutagenesis and respiratory chain dysfunction in a scleroderma model of lung fibrosis
Abstract
Reactive oxygen species (ROS) have been implemented in the etiology of pulmonary fibrosis (PF) in systemic sclerosis. In the bleomycin model, we evaluated the role of acquired mutations in mitochondrial DNA (mtDNA) and respiratory chain defects as a trigger of ROS formation and fibrogenesis. Adult male Wistar rats received a single intratracheal instillation of bleomycin and their lungs were examined at different time points. Ashcroft scores, collagen and TGFβ1 levels documented a delayed onset of PF by day 14. In contrast, increased malon dialdehyde as a marker of ROS formation was detectable as early as 24 hours after bleomycin instillation and continued to increase. At day 7, lung tissue acquired significant amounts of mtDNA deletions, translating into a significant dysfunction of mtDNA-encoded, but not nucleus-encoded respiratory chain subunits. mtDNA deletions and markers of mtDNA-encoded respiratory chain dysfunction significantly correlated with pulmonary TGFβ1 concentrations and predicted PF in a multivariate model.
Figures
References
-
- Tyndall A. J. et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Annals of the Rheumatic Diseases 69, 1809–1815, 10.1136/ard.2009.114264 (2010). - PubMed
-
- Gross T. J. & Hunninghake G. W. Idiopathic pulmonary fibrosis. N Engl J Med 345, 517–525, 10.1056/NEJMra003200 (2001). - PubMed
-
- King T. E. Jr, Pardo A. & Selman M. Idiopathic pulmonary fibrosis. Lancet 378, 1949–1961, 10.1016/S0140-6736(11)60052-4 (2011). - PubMed
-
- Daniels C. E. et al. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med 181, 604–610, 10.1164/rccm.200906-0964OC (2010). - PubMed
-
- Tashkin D. P. et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354, 2655–2666, 10.1056/NEJMoa055120 (2006). - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
